Lidocaine improves survival rate in diabetic rats submitted to acute left coronary artery ligation.
This study was designed to evaluate whether the decreased early survival rate of diabetic rats submitted to acute experimental myocardial infarction can be improved by pretreatment with lidocaine. Male Wistar rats (+/- 210 g) were rendered diabetic with i.v. injection of streptozotocin (50 mg/kg), and only those presenting 1 week later a tail-blood glucose value between 250-400 mg/dl were retained in the protocol. Eleven weeks after induction of diabetes, a bolus of lidocaine (2 mg/kg) was administered i.v. about 6 min prior to ligation of the left coronary artery under ether anesthesia in control (n = 54) and diabetic (n = 48) rats; similar studies were conducted in 53 control and 55 diabetic rats without lidocaine pretreatment. Adequate occlusion was confirmed by an elevation of plasma CK-MB levels 4 h later or by a toluidine blue injection technique in rats which died earlier. Rats were followed over 48 h and comparison in the survival rate in each group established with the Fisher's exact test. Early survival rate (measured after 20 min) was significantly decreased in diabetic rats (27% vs 45%; p = 0.04). This was greatly improved by lidocaine pretreatment in diabetic (60% vs 27%; p = 0.0013), but not in control animals (50% vs 45%; p = 0.348). Furthermore, the beneficial effect of prophylactic lidocaine observed early after coronary ligation in diabetic rats was maintained throughout the period of observation (48 h). These data suggest that the prophylactic use of lidocaine is able to reverse the increased incidence of sudden death following experimental myocardial infarction in chronically diabetic rats.
Rousseau-Migneron
S
S
Unité de Recherche sur le Diabète, Le Centre Hospitalier de l'Université Laval, Ste.-Foy, Québec, Canada.
Tancrède
G
G
Nadeau
A
A
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy; D003331:Coronary Vessels; D003402:Creatine Kinase / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D007527:Isoenzymes; D008012:Lidocaine / Q000627:therapeutic use*; D008026:Ligation; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D051381:Rats; D011919:Rats, Inbred Strains; D016019:Survival Analysis
D007527:Isoenzymes; D008012:Lidocaine; D003402:Creatine Kinase